AXAMANSARD INSURANCE PLC (MANSARD)
Nigerian Stock Exchange · Nigeria · prices in NGN · close of 21 Oct 2026
Key indicators
| Last close | NGN 11.00 |
|---|---|
| 52-week range | 10.60 – 18.70 |
| Return, 1 month / 3 months | −8.3% / −8.3% |
| Return, 1 year / 3 years | −34.1% / +166.3% |
| Trend | Below its 200-day average |
| RSI (14) | 38 |
| Volatility (1 year) | 52.0% |
| Worst drawdown (1 year) | -40.2% |
| Average daily value traded | 25.46M NGN |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Axamansard Insurance provides general and life insurance cover to individuals, families and businesses in Nigeria. Its products include motor, home, travel, health and business insurance, along with savings and investment-linked life plans. The company serves retail customers and corporate clients through branches and agents across the country, and it is based in Lagos, where it handles underwriting, claims and customer service for its policyholders.
The shares are listed on the Nigerian Stock Exchange in Nigeria under the code MANSARD, and the price on this page is in Nigerian naira (NGN). Our dividend records, which start in 2019, show payments in 5 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
AXAMANSARD INSURANCE PLC (MANSARD) trades on the Nigerian Stock Exchange in Nigeria. It last closed at NGN 11.00 on 21 October 2026.
Its price-based Market X-Ray is 40 out of 100 (a weak price profile), ranking 104 of 157 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 34.1% and over the last three months it fell 8.3%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Nigerian Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 29 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -19.1% | ||
| From 52-week high | -40.2% | ||
| Momentum | 29 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -8.3% | ||
| 6-month return | -24.1% | ||
| 12-month return, skipping the last month | -28.1% | ||
| Stability (higher is calmer) | 52 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 52.0% | ||
| Worst drawdown, 1 year (smaller is calmer) | -40.2% | ||
| Liquidity | 61 · Fair | Moderate trading activity. | |
| Average daily value traded | 25.46M NGN | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 4 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
Returns
| 1 week | +0.0% |
|---|---|
| 1 month | −8.3% |
| 3 months | −8.3% |
| 6 months | −24.1% |
| 1 year | −34.1% |
| 3 years | +166.3% |
| 5 years | +378.3% |
Signals
| 50-day / 200-day average | 11.68 / 13.60 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.12 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 26 Jun 2025 | NGN 0.4500 |
| 16 Jul 2024 | NGN 0.3400 |
| 30 Nov 2023 | NGN 0.0600 |
| 22 Jun 2023 | NGN 0.3000 |
| 24 Nov 2022 | NGN 0.0600 |
| 29 Apr 2022 | NGN 0.2500 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Nigerian Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.